ONCOLOGY
Hereditary cancer risk. Cancer genetics for diagnosed patients.
Two pathways. For those with a family history of cancer, and for patients already diagnosed who need a complete genetic picture of their disease.
PATHWAY 1
"My family has a history..."
Hereditary cancer risk assessment. For people with a family history of cancer who want to know their genetic risk before a diagnosis.
Learn more arrow_downwardPATHWAY 2
"I have been diagnosed..."
Oncology genetics for diagnosed patients. Germline and somatic analysis to identify the genetic subtype of your cancer and inform treatment.
Learn more arrow_downwardHEREDITARY CANCER RISK
Your family history is genetic information.
If cancer runs in your family, it may be driven by inherited variants that a standard test would miss. Dante sequences your entire genome to identify hereditary cancer risk across thousands of known variants.
4,000+
BRCA variants analyzed
Lynch
Syndrome markers included
6
Major gene panels covered
CHEK2, PALB2, ATM, and additional high-penetrance genes included in every whole genome analysis.
BRCA1 / BRCA2
High-penetrance variants associated with breast, ovarian, prostate, and pancreatic cancer. 4,000+ BRCA variants analyzed across the full gene sequence.
Lynch Syndrome
MLH1, MSH2, MSH6, PMS2. Hereditary condition linked to colorectal, endometrial, ovarian, and gastric cancers. Often undiagnosed until cancer presents.
CHEK2
Moderate-penetrance gene associated with breast cancer, colorectal cancer, and prostate cancer risk. Frequently missed by targeted panels.
PALB2
Partner and localizer of BRCA2. Associated with elevated breast and pancreatic cancer risk. Increasingly recognized as clinically actionable.
ATM
DNA damage repair gene. Variants associated with breast, pancreatic, and prostate cancer risk. Important for targeted therapy eligibility.
Li-Fraumeni Syndrome
TP53 mutations. Rare but high-penetrance. Associated with sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma. Early surveillance is critical.
THE PROCESS
Clinical review
Your family history and clinical context are reviewed to determine the appropriate test pathway.
Test pathway
Based on your situation, you are directed to the right scope of analysis: targeted panel or whole genome.
Kit dispatched
Your collection kit ships within 48 hours. Simple saliva collection at home. Prepaid return.
Results
Physician-ready reports delivered to your Genome Manager. Variants classified per ACMG guidelines.
ONCOLOGY GENETICS
Your diagnosis may be correct. The genetic subtype may be incomplete.
For patients already diagnosed with cancer. Germline whole genome sequencing combined with somatic analysis to identify the genetic subtype of your cancer, inform treatment decisions, and identify inherited risk for family members.
Germline WGS
Your inherited genome sequenced at 30X coverage. Identifies germline variants that may have contributed to cancer development and informs risk for biological relatives.
Somatic Analysis
Tumor-specific mutations analyzed alongside your germline genome. Identifies actionable variants, therapy targets, and resistance mechanisms specific to your cancer.
CANCER TYPES WE ANALYZE
Lung Cancer
EGFR, ALK, ROS1, KRAS, BRAF, and MET variants. Therapy selection depends on the molecular subtype.
Breast Cancer
BRCA1/2, HER2, PIK3CA, ESR1. Germline and somatic variants that determine treatment pathway and prognosis.
Ovarian Cancer
BRCA1/2, RAD51, PALB2. PARP inhibitor eligibility often depends on germline variant identification.
Colorectal Cancer
Lynch Syndrome genes, APC, KRAS, BRAF, MSI status. Informs immunotherapy eligibility and surveillance for relatives.
Endometrial Cancer
Lynch Syndrome association, POLE, PTEN, PIK3CA. Molecular classification determines adjuvant therapy approach.
Pancreatic Cancer
BRCA2, PALB2, ATM, KRAS. Germline testing informs platinum sensitivity and PARP inhibitor eligibility.
"They never added the numbers up until now when they saw the Dante Labs report."
Thomas spent years with a set of symptoms no specialist had been able to connect. It wasn't until he received his Dante Labs Whole Genome report that the underlying genetic cause was finally identified. The NHS accepted the result and changed his care plan.
Thomas, Scotland
Queen Elizabeth University Hospital Glasgow, NHS
Dante Labs results are used by physicians and hospital systems worldwide, including NHS facilities in the UK. Our reports are structured for clinical review and classified per ACMG guidelines.
The genome confirms what you suspected. Or it finds something your doctors weren't looking for.
GET IN TOUCH
Start with a conversation.
Whether you have a family history of cancer or have been diagnosed, we can help determine the right test pathway. No commitment required.